Third Phase: The third and final phase of my association with the Foundation is from 2006 as one of the Foundation Directors. In 2003 I took the job of Director of the Institute of Glycotechnology, at Tokai University as my first and the last job in Japan. During the first half of 2000, my life was hectic since I was crossing the Pacific six times a year. I gave up my US permanent residency status in 2008 and returned to Japan permanently without any personal relationship with the United States any longer. One day during my tenure at Tokai University, Mr. Ken Mizutani visited me at my Institute and invited me to serve as one of the Directors of the Foundation. Thus, I am now in the third and final phase of my association with the Foundation. Looking back I have been associated with the Foundation in three different capacities, first as a personal acquaintance and friend of Mr. Masakane Mizutani, then as an individual grantee of the Foundation, and now as one of the Directors of the Foundation. I feel that the contributions of the Foundation to the progress of glycoscience, both within Japan as well as internationally are enormous. Personaly I am most grateful that I have enjoyed every phase of my relationship with the Foundation. I have reached my 90th year and thus my remaining time is limited, However, I am glad that I can wish the best of everything for the future of the Foundation. Second Phase: The second phase of my association with the Foundation was more formal. For many external circumstances that were outside of my control, I missed the chance to return to Japan. One reason was that I was working in the United States strictly as an individual without any association with Japanese universities or research institutions. By then I was a full-time medical researcher working on molecular and biochemical aspects of genetic disorders affecting the brain. I was utilizing the then popular “knockout technology” to generate mouse models by inactivating specific genes. Particularly, I was trying to analyze the metabolic relationship between various sphingoglycolipids and the two genetically distinct β-galactosidases, both located in the lysosome. Generating mouse models with each of the enzyme inactivated, either homozygous or heterozygous, and then crossing those genotypes of two different β-galactosidases to generate all types of genotypes, were not only time-consuming but also expensive. My work was well supported by grants from the NIH, but still more research fund would have facilitated the progress. So, in 1998, I applied to the Foundation and received a research grant. Thus, the second phase of my association with the Foundation was as an individual researcher. This helped my work enormously and I reported the results in the 10-year commemorative issue of the Foundation. (Suzuki, K.: Glycolipid metabolism in the pathophysiology of genetic neurological disorders. In Glycoscience 1992-2002, Integration toward systems glycobiology, in commemoration of the 10 years of Mizutani Foundaiton for Glycoscience, pp. 90-91, 2002.)11
元のページ ../index.html#11